Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Evaluation of 2 breast cancer risk models in a benign breast disease cohort.

Frank RD, Winham SJ, Vierkant RA, Frost MH, Radisky DC, Ghosh K, Brandt KR, Sherman ME, Visscher DW, Hartmann LC, Degnim AC, Vachon CM.

Cancer. 2018 Jun 22. doi: 10.1002/cncr.31528. [Epub ahead of print]

PMID:
29932456
2.

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.

Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, Frost MH, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Carter JM, Denison LA, Broderick B, Hartmann LC, Visscher DW, Radisky DC.

J Clin Oncol. 2018 Jun 20;36(18):1840-1846. doi: 10.1200/JCO.2017.75.9480. Epub 2018 Apr 20.

PMID:
29676945
3.

A Soft Microenvironment Protects from Failure of Midbody Abscission and Multinucleation Downstream of the EMT-Promoting Transcription Factor Snail.

Simi AK, Anlaş AA, Stallings-Mann M, Zhang S, Hsia T, Cichon M, Radisky DC, Nelson CM.

Cancer Res. 2018 May 1;78(9):2277-2289. doi: 10.1158/0008-5472.CAN-17-2899. Epub 2018 Feb 26.

PMID:
29483094
4.

Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.

von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA.

Oncotarget. 2017 Oct 6;9(1):3-20. doi: 10.18632/oncotarget.21545. eCollection 2018 Jan 2.

5.

Association between mammographic breast density and histologic features of benign breast disease.

Ghosh K, Vierkant RA, Frank RD, Winham S, Visscher DW, Pankratz VS, Scott CG, Brandt K, Sherman ME, Radisky DC, Frost MH, Hartmann LC, Degnim AC, Vachon CM.

Breast Cancer Res. 2017 Dec 19;19(1):134. doi: 10.1186/s13058-017-0922-6.

6.

The exon 38-containing ARHGEF11 splice isoform is differentially expressed and is required for migration and growth in invasive breast cancer cells.

Itoh M, Radisky DC, Hashiguchi M, Sugimoto H.

Oncotarget. 2017 Sep 18;8(54):92157-92170. doi: 10.18632/oncotarget.20985. eCollection 2017 Nov 3.

7.

Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease.

Carter JM, Hoskin TL, Pena MA, Brahmbhatt R, Winham SJ, Frost MH, Stallings-Mann M, Radisky DC, Knutson KL, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2018 Feb;11(2):113-119. doi: 10.1158/1940-6207.CAPR-17-0245. Epub 2017 Nov 22.

PMID:
29167285
8.

CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.

Kerekes D, Visscher DW, Hoskin TL, Radisky DC, Brahmbhatt RD, Pena A, Frost MH, Arshad M, Stallings-Mann M, Winham SJ, Murphy L, Denison L, Carter JM, Knutson KL, Degnim AC.

Breast Cancer Res Treat. 2018 Feb;167(3):649-658. doi: 10.1007/s10549-017-4558-0. Epub 2017 Nov 1.

9.

Microfluidic chest cavities reveal that transmural pressure controls the rate of lung development.

Nelson CM, Gleghorn JP, Pang MF, Jaslove JM, Goodwin K, Varner VD, Miller E, Radisky DC, Stone HA.

Development. 2017 Dec 1;144(23):4328-4335. doi: 10.1242/dev.154823. Epub 2017 Oct 30.

10.

NanoString-based breast cancer risk prediction for women with sclerosing adenosis.

Winham SJ, Mehner C, Heinzen EP, Broderick BT, Stallings-Mann M, Nassar A, Vierkant RA, Hoskin TL, Frank RD, Wang C, Denison LA, Vachon CM, Frost MH, Hartmann LC, Aubrey Thompson E, Sherman ME, Visscher DW, Degnim AC, Radisky DC.

Breast Cancer Res Treat. 2017 Nov;166(2):641-650. doi: 10.1007/s10549-017-4441-z. Epub 2017 Aug 10.

11.

Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution.

Stallings-Mann ML, Heinzen EP, Vierkant RA, Winham SJ, Hoskin TL, Denison LA, Nassar A, Hartmann LC, Visscher DW, Frost MH, Sherman ME, Degnim AC, Radisky DC.

Breast Cancer Res Treat. 2017 Nov;166(1):133-143. doi: 10.1007/s10549-017-4413-3. Epub 2017 Jul 27.

12.

EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.

Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, Goode EL, Keeney GL, Jatoi A, Radisky DC, Radisky ES.

Genes Cancer. 2017 May;8(5-6):589-599. doi: 10.18632/genesandcancer.142.

13.

Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.

Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC.

J Cell Biochem. 2017 Nov;118(11):3531-3548. doi: 10.1002/jcb.26185. Epub 2017 Jul 17. Review.

14.

Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies.

Visscher DW, Frank RD, Carter JM, Vierkant RA, Winham SJ, Heinzen EP, Broderick BT, Denison LA, Allers TM, Johnson JL, Frost MH, Hartmann LC, Degnim AC, Radisky DC.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx035.

15.

Aromatase expression in atypical ductal hyperplasia in women.

Santen RJ, Radisky DC, Degnim A, Frost MH, Vachon CM, Ghosh K, Guestini F, McNamara KM, Sasano H.

Breast Cancer Res Treat. 2017 Jun;163(3):623-629. doi: 10.1007/s10549-017-4184-x. Epub 2017 Mar 23.

PMID:
28337664
16.

Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.

Vierkant RA, Degnim AC, Radisky DC, Visscher DW, Heinzen EP, Frank RD, Winham SJ, Frost MH, Scott CG, Jensen MR, Ghosh K, Manduca A, Brandt KR, Whaley DH, Hartmann LC, Vachon CM.

BMC Cancer. 2017 Jan 31;17(1):84. doi: 10.1186/s12885-017-3082-2.

17.

Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.

Degnim AC, Hoskin TL, Arshad M, Frost MH, Winham SJ, Brahmbhatt RA, Pena A, Carter JM, Stallings-Mann ML, Murphy LM, Miller EE, Denison LA, Vachon CM, Knutson KL, Radisky DC, Visscher DW.

Clin Cancer Res. 2017 Jul 15;23(14):3945-3952. doi: 10.1158/1078-0432.CCR-16-2026. Epub 2017 Jan 26.

PMID:
28126725
18.

Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.

Mullooly M, Yang HP, Falk RT, Nyante SJ, Cora R, Pfeiffer RM, Radisky DC, Visscher DW, Hartmann LC, Carter JM, Degnim AC, Stanczyk FZ, Figueroa JD, Garcia-Closas M, Lissowska J, Troester MA, Hewitt SM, Brinton LA, Sherman ME, Gierach GL.

Breast Cancer Res. 2017 Jan 19;19(1):8. doi: 10.1186/s13058-016-0791-4.

19.

Tissue Stiffness and Hypoxia Modulate the Integrin-Linked Kinase ILK to Control Breast Cancer Stem-like Cells.

Pang MF, Siedlik MJ, Han S, Stallings-Mann M, Radisky DC, Nelson CM.

Cancer Res. 2016 Sep 15;76(18):5277-87. doi: 10.1158/0008-5472.CAN-16-0579. Epub 2016 Aug 8.

20.

The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease.

Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, Xiao J, Radisky DC, Knutson KL, Kalari KR, Yao JZ, Baddour LM, Chia N, Degnim AC.

Sci Rep. 2016 Aug 3;6:30751. doi: 10.1038/srep30751.

21.

Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Denison LA, Carter JM, Hartmann LC, Visscher DW.

Cancer. 2016 Oct;122(19):2971-8. doi: 10.1002/cncr.30153. Epub 2016 Jun 28.

22.

Breast cancer risk by the extent and type of atypical hyperplasia.

Degnim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD, Winham SJ, Vachon CM, Dupont WD, Hartmann LC.

Cancer. 2016 Oct;122(19):3087-8. doi: 10.1002/cncr.30151. Epub 2016 Jun 28. No abstract available.

23.

MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Cichon MA, Moruzzi ME, Shqau TA, Miller E, Mehner C, Ethier SP, Copland JA, Radisky ES, Radisky DC.

Cancer Res. 2016 Jun 15;76(12):3520-30. doi: 10.1158/0008-5472.CAN-15-3465. Epub 2016 Apr 13.

24.

Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.

Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA, Tun HW.

Oncotarget. 2016 May 31;7(22):32156-71. doi: 10.18632/oncotarget.8537.

25.

Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N.

Biochem J. 2016 May 15;473(10):1329-41. doi: 10.1042/BJ20151410. Epub 2016 Mar 8.

26.

Foxa1 is essential for mammary duct formation.

Liu Y, Zhao Y, Skerry B, Wang X, Colin-Cassin C, Radisky DC, Kaestner KH, Li Z.

Genesis. 2016 May;54(5):277-85. doi: 10.1002/dvg.22929. Epub 2016 Mar 29.

27.

Natural history of age-related lobular involution and impact on breast cancer risk.

Radisky DC, Visscher DW, Frank RD, Vierkant RA, Winham S, Stallings-Mann M, Hoskin TL, Nassar A, Vachon CM, Denison LA, Hartmann LC, Frost MH, Degnim AC.

Breast Cancer Res Treat. 2016 Feb;155(3):423-30. doi: 10.1007/s10549-016-3691-5. Epub 2016 Feb 4.

28.

Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma.

Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC.

Genes Cancer. 2015 Nov;6(11-12):480-9.

29.

Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC.

Cancer. 2016 Feb 1;122(3):378-85. doi: 10.1002/cncr.29766. Epub 2015 Oct 29.

30.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

31.

Localized Smooth Muscle Differentiation Is Essential for Epithelial Bifurcation during Branching Morphogenesis of the Mammalian Lung.

Kim HY, Pang MF, Varner VD, Kojima L, Miller E, Radisky DC, Nelson CM.

Dev Cell. 2015 Sep 28;34(6):719-26. doi: 10.1016/j.devcel.2015.08.012. Epub 2015 Sep 18.

32.

ERβ expression and breast cancer risk prediction for women with atypias.

Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2015 Nov;8(11):1084-92. doi: 10.1158/1940-6207.CAPR-15-0198. Epub 2015 Aug 14.

33.

Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study.

Nassar A, Visscher DW, Degnim AC, Frank RD, Vierkant RA, Frost M, Radisky DC, Vachon CM, Kraft RA, Hartmann LC, Ghosh K.

Breast Cancer Res Treat. 2015 Sep;153(2):397-405. doi: 10.1007/s10549-015-3535-8. Epub 2015 Aug 12.

34.

Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.

Degnim AC, Nassar A, Stallings-Mann M, Keith Anderson S, Oberg AL, Vierkant RA, Frank RD, Wang C, Winham SJ, Frost MH, Hartmann LC, Visscher DW, Radisky DC.

Breast Cancer Res Treat. 2015 Aug;152(3):687-94. doi: 10.1007/s10549-015-3513-1. Epub 2015 Jul 23.

35.

Mechanically patterning the embryonic airway epithelium.

Varner VD, Gleghorn JP, Miller E, Radisky DC, Nelson CM.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9230-5. doi: 10.1073/pnas.1504102112. Epub 2015 Jul 13.

36.

Matrix metalloproteinases as breast cancer drivers and therapeutic targets.

Radisky ES, Radisky DC.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1144-63. Review.

37.

Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort.

Nassar A, Hoskin TL, Stallings-Mann ML, Degnim AC, Radisky DC, Frost MH, Vierkant RA, Hartmann LC, Visscher DW.

Breast Cancer Res Treat. 2015 May;151(1):89-97. doi: 10.1007/s10549-015-3370-y. Epub 2015 Apr 12.

38.

Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.

Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P.

Mol Cancer Ther. 2015 Jun;14(6):1306-16. doi: 10.1158/1535-7163.MCT-14-0945. Epub 2015 Apr 7.

39.

Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion.

Cichon MA, Nelson CM, Radisky DC.

Cancer Inform. 2015 Feb 9;14(Suppl 3):1-13. doi: 10.4137/CIN.S18965. eCollection 2015.

40.

Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia.

Liou GY, Döppler H, Braun UB, Panayiotou R, Scotti Buzhardt M, Radisky DC, Crawford HC, Fields AP, Murray NR, Wang QJ, Leitges M, Storz P.

Nat Commun. 2015 Feb 20;6:6200. doi: 10.1038/ncomms7200.

41.

Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Said SM, Visscher DW, Nassar A, Frank RD, Vierkant RA, Frost MH, Ghosh K, Radisky DC, Hartmann LC, Degnim AC.

Cancer. 2015 May 15;121(10):1548-55. doi: 10.1002/cncr.29243. Epub 2015 Jan 13.

42.

Model for individualized prediction of breast cancer risk after a benign breast biopsy.

Pankratz VS, Degnim AC, Frank RD, Frost MH, Visscher DW, Vierkant RA, Hieken TJ, Ghosh K, Tarabishy Y, Vachon CM, Radisky DC, Hartmann LC.

J Clin Oncol. 2015 Mar 10;33(8):923-9. doi: 10.1200/JCO.2014.55.4865. Epub 2015 Jan 26.

43.
44.

Lattice-based model of ductal carcinoma in situ suggests rules for breast cancer progression to an invasive state.

Boghaert E, Radisky DC, Nelson CM.

PLoS Comput Biol. 2014 Dec 4;10(12):e1003997. doi: 10.1371/journal.pcbi.1003997. eCollection 2014 Dec.

45.

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.

Bria E, Di Modugno F, Sperduti I, Iapicca P, Visca P, Alessandrini G, Antoniani B, Pilotto S, Ludovini V, Vannucci J, Bellezza G, Sidoni A, Tortora G, Radisky DC, Crinò L, Cognetti F, Facciolo F, Mottolese M, Milella M, Nisticò P.

Oncotarget. 2014 Nov 30;5(22):11054-63.

46.
47.

Clinical characteristics of breast cancers in African-American women with benign breast disease: a comparison to the surveillance, epidemiology, and end results program.

Mitro SD, Ali-Fehmi R, Bandyopadhyay S, Alosh B, Albashiti B, Radisky DC, Frost MH, Degnim AC, Ruterbusch JJ, Cote ML.

Breast J. 2014 Nov-Dec;20(6):571-7. doi: 10.1111/tbj.12331. Epub 2014 Sep 8.

48.

Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.

Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA.

Oncotarget. 2014 Jul 30;5(14):5320-34.

49.

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA.

Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.

50.

CCAAT/enhancer binding protein beta (C/EBPβ) isoform balance as a regulator of epithelial-mesenchymal transition in mouse mammary epithelial cells.

Miura Y, Hagiwara N, Radisky DC, Hirai Y.

Exp Cell Res. 2014 Sep 10;327(1):146-55. doi: 10.1016/j.yexcr.2014.05.019. Epub 2014 May 29.

PMID:
24881817

Supplemental Content

Loading ...
Support Center